Slate Medicines
Slate Medicines

Slate Medicines

DR7Ahrefs DR: 7/100. Bottom 25%. Measured by Ahrefs. Median 44.Agent51Agent Readiness: 51/100. Top 25%. Measured by StartupHub.ai. Median 41.Speed69Site Speed: 69/100. Above median. Measured by Google PageSpeed. Median 62.Trust86Data Trust: 86/100. Top 25%. Measured by StartupHub.ai. Median 61.

Advancing anti-PACAP therapies for the prevention of migraine and other headache disorders.

2024ActiveCambridge, United States

About

Slate Medicines is a biotechnology company focused on developing novel anti-PACAP (Pituitary Adenylate Cyclase-Activating Polypeptide) therapies for the prevention and treatment of migraine and other severe headache disorders. The company launched with a significant Series A financing to support its therapeutic pipeline.

Key facts

Website
slatemedicines.com
Headquarters
Cambridge, Massachusetts, United States
Founded
2024
Total funding
$130M (Series A)
Business model
B2B

Funding rounds

Funding rounds raised by Slate Medicines
DateRoundAmountLead investors
24 Feb 2026Series A$130M

Tech stack

Detected on slatemedicines.com, last scanned 16 Oct 2026.

Frontend
jQuery
Analytics
Google Analytics 4
CMS / Builders
WordPress
CDN
Cloudflare
Email provider
Microsoft 365

Slate Medicines scores 7. Does yours?

That is its Ahrefs DR: the backlink strength of a domain, on the Ahrefs 0 to 100 scale. Paste your website and you get yours in about a minute.

Add first review

Frequently asked

Is Slate Medicines trustworthy and reputable?

StartupHub's Data Trust & Reputation score for Slate Medicines is 86 out of 100, a trusted rating, based on site security posture, privacy practices, malware and phishing checks, and public reputation signals.

How much funding has Slate Medicines raised?

Slate Medicines has raised a total of $130M in funding. The most recent round on record is Series A.